CD19 and systemic lupus erythematosus: Initial clinical applications of anti-CD19 CAR-T cells in patients with refractory SLE have shown rapid clinical remission, sustained B-cell depletion, and swift elimination of serum anti-double-stranded DNA antibodies, with manageable adverse effects [94].